miRagen, Santaris, Servier deal

Servier partnered with miRagen to develop and commercialize microRNA-targeting products for cardiovascular disease. The deal includes miRagen's preclinical programs targeting microRNA-208 ( miR-208) and miR-15/195, as well as a cardiovascular microRNA modulator yet to be identified. miRagen is eligible for up to $352 million, which includes $45 million in upfront, research and near-term milestone payments over the next three years, as well as additional clinical and commercial milestones.

Servier will have rights outside of the U.S. and Japan, and will be responsible for funding all development through Phase II testing. miRagen retains U.S. and Japanese rights and will have an option to co-sponsor Phase III trials. ...